Eric J. Lavonas
Eric J. Lavonas has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
Richard C. Dart
Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO
4 shared publications- Richard C. Dart
Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, CO, United States
4 shared publications - Jeffrey Brent
University of Colorado, School of Medicine
3 shared publications - Steven A. Seifert
New Mexico Poison and Drug Information Center, Albuquerque, NM, USA
3 shared publications - Andrew Rosenblum
Institute for Treatment and Services Research, National Development and Research Institutes, New York, NY 10010, USA
2 shared publications Becki Bucher-Bartelson
Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO
2 shared publications
Latest Publications
- 25 June 2017
- Published by Springer Nature
- p. 991-1008
Lithium
- 27 September 2016
- Published by Springer Nature
- p. 1-18
Lithium
- Open Access
- 15 May 2015
- Published by Springer Nature in BMC Emergency Medicine
- Vol. 15 (1) , 1-21
Prospective study of recovery from copperhead snake envenomation: an observational study
Although much is known about signs, symptoms, and management in the acute phase of crotaline snake envenomation, little is known about signs, symptoms, function, and quality of life during the recovery phase. The purpose of this observational pilot investigation is to evaluate the utility of several clinical outcome instruments in the setting of copperhead snakebite, and to characterize the clinical course of recovery. This is a multi-center prospective, open-label, observational study of patients envenomated by copperhead snakes. We administered the Disabilities of the Arm, Shoulder, and Hand (DASH), Lower Extremity Functional Scale (LEFS), Patient-Specific Functional Scale (PSFS), Work Productivity and Ability Impairment: Special Health Problem (WPAI: SHP), Patients’ Global Impression of Change (PGIC), Patient’s Global Assessment of Recovery (PGAR), and SF-36 instruments, obtained numeric pain rating scales, and measured grip strength, walking speed, and swelling prior to hospital discharge and 3, 7, 14, 21, and 28 days after envenomation. 20 subjects were enrolled; none were lost to follow-up. Most (80%) had moderate severity swelling, and most (75%) received antivenom. Across the broad range of measures, abnormalities of pain, swelling, impairments of physical and role function, and quality of life persisted for 7–14 days in most subjects. Validated self-reported outcome measures, such as the DASH, LEFS, PSFS, PGIC, SF-36, and the daily activities impairment portion of the WPAI: SHP were more responsive than measurements of swelling or walking speed. Data quality issues limited the utility of the work impairment portion of the WPAI: SHP. Residual signs, symptoms, and impairment in some subjects lasted through the 28-day study period. The study design precluded any assessment of the effectiveness of antivenom. Signs, symptoms, impaired function, and decreased quality of life typically last 7 – 14 days after copperhead envenomation. Several tools appear responsive and useful in studying recovery from pit viper envenomation. ClinicalTrials.gov NCT01651299
- 15 May 2015
- Published by Springer Nature in BMC Emergency Medicine
- Vol. 15 (1) , 1-21
Open AccessProspective study of recovery from copperhead snake envenomation: an observational study
Although much is known about signs, symptoms, and management in the acute phase of crotaline snake envenomation, little is known about signs, symptoms, function, and quality of life during the recovery phase. The purpose of this observational pilot investigation is to evaluate the utility of several clinical outcome instruments in the setting of copperhead snakebite, and to characterize the clinical course of recovery. This is a multi-center prospective, open-label, observational study of patients envenomated by copperhead snakes. We administered the Disabilities of the Arm, Shoulder, and Hand (DASH), Lower Extremity Functional Scale (LEFS), Patient-Specific Functional Scale (PSFS), Work Productivity and Ability Impairment: Special Health Problem (WPAI: SHP), Patients’ Global Impression of Change (PGIC), Patient’s Global Assessment of Recovery (PGAR), and SF-36 instruments, obtained numeric pain rating scales, and measured grip strength, walking speed, and swelling prior to hospital discharge and 3, 7, 14, 21, and 28 days after envenomation. 20 subjects were enrolled; none were lost to follow-up. Most (80%) had moderate severity swelling, and most (75%) received antivenom. Across the broad range of measures, abnormalities of pain, swelling, impairments of physical and role function, and quality of life persisted for 7–14 days in most subjects. Validated self-reported outcome measures, such as the DASH, LEFS, PSFS, PGIC, SF-36, and the daily activities impairment portion of the WPAI: SHP were more responsive than measurements of swelling or walking speed. Data quality issues limited the utility of the work impairment portion of the WPAI: SHP. Residual signs, symptoms, and impairment in some subjects lasted through the 28-day study period. The study design precluded any assessment of the effectiveness of antivenom. Signs, symptoms, impaired function, and decreased quality of life typically last 7 – 14 days after copperhead envenomation. Several tools appear responsive and useful in studying recovery from pit viper envenomation. ClinicalTrials.gov NCT01651299
- 1 March 2015
- Published by Wiley in Academic Emergency Medicine
- Vol. 22 (3) , 308-314
Time to Antivenom Administration Is Not Associated With Total Antivenom Dose Administered in a Copperhead‐predominant Snakebite Population
To prevent unnecessary antivenom administration in crotaline snakebite, observation for progression is recommended for the patient with minor envenomation whose condition is stable and not progressing. The objective of this study was to determine the association between the time from bite to initial antivenom administration (Time(AV)) and the total amount of antivenom administered (Total(AV)) and to determine what proportion of patients did not have progression of the envenomation syndrome and did not receive antivenom.This was a retrospective chart review of patients presenting with crotaline snakebite within 24 hours from 2009 through 2012. Blinded dual-chart abstraction and strict data point definitions were used. Spearman correlation was used to determine the association between Time(AV) and Total(AV). A general linear model was used to examine this association using Time(AV) categorized to early and late administration, adjusted for likely confounders. Confounders included age, extremity involved, initial severity, and year of envenomation.Ninety-five eligible patients were analyzed with 45 (47%) males and a mean (±SD) age of 36.5 (±21.1) years. Eighty-five (89%) received antivenom, with a median Time(AV) of 3.3 hours (interquartile range [IQR] = 2.5 to 5.2 hours). The median Total(AV) was 10 vials (IQR = 6 to 14 vials). The univariate analysis showed a small but statistically significant decrease in Total(AV) given to patients treated greater than 6 hours from bite (r = -0.26, p = 0.015). The multivariate analysis resulted in no significant relation between early or late Time(AV) and Total(AV) (p = 0.10) after adjustment for confounders. Most minimal envenomation syndromes (80%, or 41 of 51) progressed to moderate grade envenomations.Time(AV) was not associated with Total(AV) when adjusted for likely confounders and supports current recommendations to observe for progression in minor envenomation. The majority of envenomations progressed, resulting in only a small proportion of patients not eventually receiving antivenom. The authors recommend observation in an environment where the patient can be adequately reassessed for progression of the envenomation.
- 1 March 2015
- Published by Wiley in Academic Emergency Medicine
- Vol. 22 (3) , 308-314
Time to Antivenom Administration Is Not Associated With Total Antivenom Dose Administered in a Copperhead‐predominant Snakebite Population
To prevent unnecessary antivenom administration in crotaline snakebite, observation for progression is recommended for the patient with minor envenomation whose condition is stable and not progressing. The objective of this study was to determine the association between the time from bite to initial antivenom administration (Time(AV)) and the total amount of antivenom administered (Total(AV)) and to determine what proportion of patients did not have progression of the envenomation syndrome and did not receive antivenom.This was a retrospective chart review of patients presenting with crotaline snakebite within 24 hours from 2009 through 2012. Blinded dual-chart abstraction and strict data point definitions were used. Spearman correlation was used to determine the association between Time(AV) and Total(AV). A general linear model was used to examine this association using Time(AV) categorized to early and late administration, adjusted for likely confounders. Confounders included age, extremity involved, initial severity, and year of envenomation.Ninety-five eligible patients were analyzed with 45 (47%) males and a mean (±SD) age of 36.5 (±21.1) years. Eighty-five (89%) received antivenom, with a median Time(AV) of 3.3 hours (interquartile range [IQR] = 2.5 to 5.2 hours). The median Total(AV) was 10 vials (IQR = 6 to 14 vials). The univariate analysis showed a small but statistically significant decrease in Total(AV) given to patients treated greater than 6 hours from bite (r = -0.26, p = 0.015). The multivariate analysis resulted in no significant relation between early or late Time(AV) and Total(AV) (p = 0.10) after adjustment for confounders. Most minimal envenomation syndromes (80%, or 41 of 51) progressed to moderate grade envenomations.Time(AV) was not associated with Total(AV) when adjusted for likely confounders and supports current recommendations to observe for progression in minor envenomation. The majority of envenomations progressed, resulting in only a small proportion of patients not eventually receiving antivenom. The authors recommend observation in an environment where the patient can be adequately reassessed for progression of the envenomation.
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e95
Buprenorphine/naloxone pediatric ingestion: Exposure rates differ between film and tablet formulations
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e95
Buprenorphine/naloxone pediatric ingestion: Exposure rates differ between film and tablet formulations
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e257
Buprenorphine/naloxone abuse and diversion: Film rates are less than tablet rates
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e257
Buprenorphine/naloxone abuse and diversion: Film rates are less than tablet rates
- Open Access
- 1 July 2014
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 47 (1) , 27-34
Abuse and diversion of buprenorphine sublingual tablets and film
- 1 July 2014
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 47 (1) , 27-34
Open AccessAbuse and diversion of buprenorphine sublingual tablets and film
- 1 January 2014
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 63 (1) , 71-78.e1
Medically Significant Late Bleeding After Treated Crotaline Envenomation: A Systematic Review
- 1 January 2014
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 63 (1) , 71-78.e1
Medically Significant Late Bleeding After Treated Crotaline Envenomation: A Systematic Review
- Open Access
- 1 November 2013
- Published by Elsevier in The Journal of Pediatrics
- Vol. 163 (5) , 1377-1383.e3
Root Causes, Clinical Effects, and Outcomes of Unintentional Exposures to Buprenorphine by Young Children
- 1 November 2013
- Published by Elsevier in The Journal of Pediatrics
- Vol. 163 (5) , 1377-1383.e3
Open AccessRoot Causes, Clinical Effects, and Outcomes of Unintentional Exposures to Buprenorphine by Young Children